trial · primary record
Empagliflozin (SGLT2i)
No Reflow Phenomenon
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2027-08 |
| Primary endpoint | Incidence of angiographic no-reflow/impaired myocardial reperfusion |
| Registry ID | NCT07898709 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:19.252Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07898709
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.